miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients.
(2013) In British Journal of Cancer 108(8). p.1668-1676- Abstract
- Background:The microRNA-205 (miR-205) has been shown to be deregulated in prostate cancer (PCa). Here we continue to investigate the prognostic and therapeutic potential of this microRNA.Methods:The expression of miR-205 is measured by qRT-PCR and in situ hybridisation in a well-documented PCa cohort. An AGO2-based RIP-Chip assay is used to identify targets that are verified with western blots, luciferase reporter assay, ELISA and immunohistochemistry.Results:The expression of miR-205 is inversely correlated to the occurrence of metastases and shortened overall survival, and is lower in castration-resistant PCa patients. The miR-205 expression is mainly localised to the basal cells of benign prostate tissues. Genes regulated by miR-205 are... (More)
- Background:The microRNA-205 (miR-205) has been shown to be deregulated in prostate cancer (PCa). Here we continue to investigate the prognostic and therapeutic potential of this microRNA.Methods:The expression of miR-205 is measured by qRT-PCR and in situ hybridisation in a well-documented PCa cohort. An AGO2-based RIP-Chip assay is used to identify targets that are verified with western blots, luciferase reporter assay, ELISA and immunohistochemistry.Results:The expression of miR-205 is inversely correlated to the occurrence of metastases and shortened overall survival, and is lower in castration-resistant PCa patients. The miR-205 expression is mainly localised to the basal cells of benign prostate tissues. Genes regulated by miR-205 are enriched in, for example, the MAPK/ERK, Toll-like receptor and IL-6 signaling pathways. We demonstrate binding of miR-205 to the 3'UTR of androgen receptor (AR) and decrease of both AR transcript and protein levels. This finding was corroborated in the patient cohort were miR-205 expression inversely correlated to AR immunostaining in malignant prostate cells and to serum levels of prostate-specific antigen, an androgen-regulated protein.Conclusion:Taken together, these findings imply that miR-205 might have therapeutic potential, especially for the castration resistant and currently untreatable form of PCa.British Journal of Cancer advance online publication, 9 April 2013; doi:10.1038/bjc.2013.131 www.bjcancer.com. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3733987
- author
- Hagman, Zandra
LU
; Haflidadottir, Benedikta
LU
; Ceder, Jens
LU
; Larne, Olivia
LU
; Bjartell, Anders
LU
; Lilja, Hans
LU
; Edsjö, Anders LU and Ceder, Yvonne LU
- organization
-
- Clinical Chemistry, Malmö (research group)
- Urological research, Malmö (research group)
- Urological cancer, Malmö (research group)
- Department of Translational Medicine
- Medical Molecular Biology (research group)
- EpiHealth: Epidemiology for Health
- BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- British Journal of Cancer
- volume
- 108
- issue
- 8
- pages
- 9 pages
- publisher
- Nature Publishing Group
- external identifiers
-
- wos:000318406400015
- pmid:23571738
- scopus:84877017881
- pmid:23571738
- ISSN
- 1532-1827
- DOI
- 10.1038/bjc.2013.131
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Clinical Chemistry, Malmö (013016000), Molecular Medicine (013031200), Division of urological research (013243410), Division of Urological Cancers (013243420)
- id
- ec1c658f-67b3-4659-a7bc-f681a328f3da (old id 3733987)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23571738?dopt=Abstract
- date added to LUP
- 2016-04-01 11:02:35
- date last changed
- 2022-05-19 02:19:59
@article{ec1c658f-67b3-4659-a7bc-f681a328f3da, abstract = {{Background:The microRNA-205 (miR-205) has been shown to be deregulated in prostate cancer (PCa). Here we continue to investigate the prognostic and therapeutic potential of this microRNA.Methods:The expression of miR-205 is measured by qRT-PCR and in situ hybridisation in a well-documented PCa cohort. An AGO2-based RIP-Chip assay is used to identify targets that are verified with western blots, luciferase reporter assay, ELISA and immunohistochemistry.Results:The expression of miR-205 is inversely correlated to the occurrence of metastases and shortened overall survival, and is lower in castration-resistant PCa patients. The miR-205 expression is mainly localised to the basal cells of benign prostate tissues. Genes regulated by miR-205 are enriched in, for example, the MAPK/ERK, Toll-like receptor and IL-6 signaling pathways. We demonstrate binding of miR-205 to the 3'UTR of androgen receptor (AR) and decrease of both AR transcript and protein levels. This finding was corroborated in the patient cohort were miR-205 expression inversely correlated to AR immunostaining in malignant prostate cells and to serum levels of prostate-specific antigen, an androgen-regulated protein.Conclusion:Taken together, these findings imply that miR-205 might have therapeutic potential, especially for the castration resistant and currently untreatable form of PCa.British Journal of Cancer advance online publication, 9 April 2013; doi:10.1038/bjc.2013.131 www.bjcancer.com.}}, author = {{Hagman, Zandra and Haflidadottir, Benedikta and Ceder, Jens and Larne, Olivia and Bjartell, Anders and Lilja, Hans and Edsjö, Anders and Ceder, Yvonne}}, issn = {{1532-1827}}, language = {{eng}}, number = {{8}}, pages = {{1668--1676}}, publisher = {{Nature Publishing Group}}, series = {{British Journal of Cancer}}, title = {{miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients.}}, url = {{http://dx.doi.org/10.1038/bjc.2013.131}}, doi = {{10.1038/bjc.2013.131}}, volume = {{108}}, year = {{2013}}, }